Rectal cancer is often diagnosed when a doctor orders tests to find the cause of rectal bleeding or iron deficiency anemia. A colonoscopy is the most accurate of these tests. In a colonoscopy, a doctor uses a thin, flexible, lighted tube with a video camera at its tip (a colonoscope) to view the inside of your colon and rectum.

Sometimes rectal cancer has no noticeable symptoms. People without symptoms may learn they have rectal cancer when they have a screening colonoscopy — that is, a colonoscopy recommended at age 50 for everyone with an average risk of colorectal cancer.

It's usually possible to remove small tissue samples (biopsies) from suspicious-looking areas during a colonoscopy. Laboratory analysis of this tissue helps pin down the diagnosis.

Staging rectal cancer

Once you are diagnosed with rectal cancer, the next step is to determine the cancer's extent (stage). Staging helps guide decisions about the most appropriate treatments for you. The following blood tests and imaging studies are involved in staging rectal cancer:

  • Complete blood count (CBC). This test reports the numbers of different types of cells in your blood. A CBC shows whether your red blood cell count is low (anemia), which suggests that a tumor is causing blood loss. A high level of white blood cells is a sign of infection, which is a risk if a rectal tumor grows through the wall of the rectum.
  • Carcinoembryonic antigen (CEA). Cancers sometimes produce substances called tumor markers that can be detected in blood. One such marker, carcinoembryonic antigen (CEA), may be higher than normal in people with colorectal cancer. CEA testing is particularly useful in monitoring your response to treatment.
  • Chemistry panel. This test measures a number of chemicals in the blood. Abnormal levels of some of these chemicals may suggest that cancer has spread to the liver. High levels of other chemicals may indicate problems with other organs, such as the kidneys.
  • CT (computed tomography) scan of the chest. This imaging test helps determine whether rectal cancer has spread to other organs, such as the liver and lungs.
  • MRI (magnetic resonance imaging) of the pelvis. An MRI provides a detailed image of the muscles, organs and other tissues surrounding a tumor in the rectum. An MRI also shows the lymph nodes near the rectum and different layers of tissue in the rectal wall.

Rectal cancer stages

Rectal cancers fall into one of five possible stages (stage 0 through stage 4). The stages, in simplified form, are:

  • Stage 0. Cancer cells on the surface of the rectal lining (mucosa), sometimes within a polyp
  • Stage I. Tumor extending below the rectal mucosa, sometimes penetrating into the rectal wall
  • Stage II. Tumor extending into or through the rectal wall, sometimes reaching and growing on or sticking to tissues next to the rectum
  • Stage III. Tumor invading lymph nodes next to the rectum, as well as structures and tissues outside the rectal wall
  • Stage IV. Tumor spread to a distant organ or lymph nodes distant from the rectum

Staging also involves examining a sample of tissue taken from the tumor (a biopsy) to determine the tumor's grade. Low-grade tumors tend to grow and spread slowly. In contrast, high-grade tumors grow and spread quickly, so they may need more-aggressive treatment.


Rectal cancer often requires more than one treatment type (modality), an approach known as multimodal therapy. In general, the treatment modalities used in rectal cancer are the same ones used to treat many other types of cancer. They are:

  • Surgery to remove the tumor.
  • Chemotherapy, usually consisting of two or more drugs that target cancer cells. In people with rectal cancer, chemotherapy is often used along with radiation therapy, either before or after surgery.
  • Radiation therapy, which uses high-powered beams, such as X-rays, to kill cancer cells.


Your surgical options depend on a number of factors, including:

  • The stage and grade of the cancer
  • The location of the tumor in the rectum
  • The size of the tumor
  • Your age
  • Your general health
  • Your medical history
  • Your preferences after you learn about different procedures

Some of the procedures commonly used to treat rectal cancer are:

  • Abdominoperineal resection with end colostomy
    Abdominoperineal resection (APR) offers the best chance of cure for rectal tumors located extremely close to the anal sphincter. With cancer in this location, the surgeon has to remove both the tumor and the sphincter. Otherwise, it's not possible to take a margin of healthy tissue on all sides of the tumor — and clear or healthy margins reduce the risk that the cancer will return.

    After APR, it is no longer possible to pass stool through the anus. An end colostomy connects the end of the colon that was attached to the rectum before APR to a surgical opening (stoma) in the lower abdomen. Stool then passes into a removable pouch placed over the stoma.

  • Coloanal anastomosis
    This sphincter-sparing procedure may be an option for rectal cancer surgery if the tumor is at least .39 inch (1 centimeter) above the top of the anal sphincter. The surgeon removes the entire rectum and enough of the surrounding tissue to achieve clear margins. Then the remaining end of the colon may be shaped into a pouch that is connected to the colon. Alternatively, the end of the colon may be connected directly to the anus.

  • Low anterior resection
    This procedure, which also leaves the anus intact, may be performed when the tumor is located in the upper part of the rectum. The surgeon removes the tumor and a margin of healthy tissue around it, leaving the lower part of the rectum. The end of the colon is then attached to the remaining section of the rectum.

  • Local excision
    Local excision takes out the rectal tumor, along with a margin of healthy tissue and the section of rectal wall beneath the tumor. This technique is generally reserved for early, small stage 1 rectal cancers, after a biopsy shows that the tumor is unlikely to spread or recur.

    Unlike the other procedures listed, local excision does not include lymph-node removal. Instead, the excised tissue is examined in a laboratory to make sure the tumor doesn't have features that suggest more-advanced cancer than expected. If any of these features are present, a standard operation may be necessary.

  • More-extensive surgery
    People with rectal cancer associated with Crohn's disease, ulcerative colitis or a genetic predisposition to colorectal cancer typically need surgery that is more extensive than are the procedures described here. Chemotherapy is also needed before or after surgery.

Combination therapy

Standard treatment for stage II and stage III rectal cancers is typically a combination of chemotherapy and radiation (chemoradiotherapy) given before surgery (preoperatively). This approach is also an option for treating some stage I rectal cancers that have a high risk of recurring.

Benefits of preoperative chemoradiotherapy include:

  • Increased response to radiation because of chemotherapy's effect on cancer cells
  • Reduced tumor size
  • Lowered cancer stage in some cases
  • Better chance that surgery will leave the anal area intact (sphincter-sparing surgery)
  • Lower risk of cancer recurrence

The usual period between preoperative chemoradiotherapy and surgery is about six weeks. After surgery, most people also have additional chemotherapy to destroy any remaining cancer cells.

Stage IV rectal cancer

Some of the treatments used in stage II and III rectal cancers may also be appropriate for cancers in stage IV. By definition, though, stage IV rectal cancer has spread (metastasized) to a different part of the body, usually the liver.

In some cases, a metastatic tumor may appear in the liver when the primary tumor is still confined mainly to the rectum and nearby lymph nodes. If this happens, your doctor may recommend surgery to remove both the primary tumor and the liver tumor at once.

In other cases, the primary tumor may have spread to organs near the rectum, such as the uterus and ovaries, before liver metastasis appears. Complex surgery and reconstruction of pelvic structures may be possible in these cases as well.

Drugs for stage IV rectal cancer

Chemotherapy may extend life for people with stage IV rectal cancer, as may radiation therapy in some cases. Either treatment may be given after surgery, while chemotherapy is more commonly used before surgery. Chemotherapy or radiation may be used to relieve symptoms in cases where the cancer is too extensive for surgery.

People with stage IV rectal cancer may receive one of three newer FDA-approved drugs in addition to cancer chemotherapy. These drugs, called biologics, target cancer-cell traits that allow tumors to grow. The addition of a biologic drug to standard chemotherapy has been found to improve response to treatment in certain cases of colorectal cancer. Therapy that includes biologics is called targeted therapy.

The FDA-approved biologics used with chemotherapy in first line treatment of stage 4 colorectal cancer are:

  • Bevacizumab (Avastin)
  • Cetuximab (Erbitux)
  • Panitumumab (Vectibix)

Supportive (palliative) care

Palliative care is focused on providing relief from pain and other symptoms of a serious illness. Palliative care specialists work with you, your family and your other doctors to provide an extra layer of support that complements your ongoing care.

An example of palliative care might be surgery to relieve a blockage of the rectum in order to improve your symptoms.

Palliative care is provided by a team of doctors, nurses and other specially trained professionals. Palliative care teams aim to improve the quality of life for people with cancer and their families. This form of care is offered alongside curative or other treatments you may be receiving.

Clinical trials

Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this disease.

Preparing for your appointment

If your doctor suspects you may have rectal cancer, you'll likely be referred to one or more specialists who treat rectal cancer, including:

  • A doctor who treats digestive diseases (gastroenterologist)
  • A doctor who treats cancer (oncologist)
  • A surgeon specializing in procedures involving the colon and rectum (colorectal surgeon)
  • A doctor who uses radiation to treat cancer (radiation oncologist)

Here are some things you can do before you meet with these doctors:

  • Find out if there's anything you need to do before your appointment, such as avoid certain foods or medications.
  • Make a list of all your medications, including vitamins or supplements.
  • Consider taking a family member or friend along to take notes on what your doctors say, so that you can concentrate on listening.
  • Write down questions to ask your doctor.

For rectal cancer, here are some questions you may want to ask:

  • In what part of the rectum is my cancer located?
  • What is the stage of my rectal cancer?
  • Has my rectal cancer spread to other parts of my body?
  • Will I need more tests?
  • What are the treatment options?
  • How much does each treatment increase my chances of a cure?
  • What are the potential side effects of each treatment?
  • How will each treatment affect my daily life?
  • Is there one treatment you feel is best for me?
  • What would you recommend to a family member or friend in my same situation?
  • How much time can I take to make my decision about treatment?
  • Should I seek a second opinion?
  • Are there any brochures or other printed material that I can take with me? What websites do you recommend?

Rectal cancer care at Mayo Clinic

Oct. 09, 2019
  1. AskMayoExpert. Colorectal cancer. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
  2. Bailey HR, et al., eds. Management of rectal cancer. In: Colorectal Surgery. Philadelphia, Pa.: Saunders Elsevier; 2013. http://www.clinicalkey.com. Accessed Jan. 4, 2017.
  3. Rectal cancer treatment (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/treatment/rectal/HealthProfessional. Accessed Dec. 30, 2016.
  4. Fischer J, et al. Outcome for stage II and III rectal and colon cancer equally good after treatment improvement over three decades. International Journal of Colorectal Disease. 2015;30:797.
  5. Peres-Ruiz E, et al. Immunological landscape and clinical management of rectal cancer. Frontiers in Immunology. 2016;7:1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761957/. Accessed Feb. 22, 2017.
  6. Niederhuber JE, et al., eds. Cancer of the rectum. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed Jan. 4, 2017.
  7. Etzioni DA, et al. Patient survival after surgical treatment of rectal cancer: Impact of surgeon and hospital characteristics. Cancer. 2014;120:2472.
  8. Renouf DJ, et al. Improvements in 5-year outcomes of stage II/III rectal cancer relative to colon cancer. American Journal of Clinical Oncology. 2013;36:558.
  9. Colorectal cancer. American Cancer Society. https://www.cancer.org/cancer/colon-rectal-cancer.html. Accessed Jan. 4, 2017.
  10. Macrae FA, et al. Clinical presentation, diagnosis, and staging of colorectal cancer. http://www.uptodate.com/home. Accessed Feb. 4, 2016.
  11. Ryan DP, et al. Overview of the management of rectal adenocarcinoma. http://www.uptodate.com/home. Accessed Feb. 4, 2016.
  12. Mahipal A, et al. Role of biologics in first-line treatment of colorectal cancer. Journal of Oncology Practice. 2016:12:1219.
  13. Holman FA, et al. Results of a pooled analysis of IOERT containing multimodality treatment for locally recurrent rectal cancer: Results of 565 patients of two major treatment centers. European Journal of Surgical Oncology. 2017;43:107.
  14. Holman FA, et al. Results of intraoperative electron beam radiotherapy containing multimodality treatment for locally unresectable T4 rectal cancer: A pooled analysis of the Mayo Clinic Rochester and Catharina Hospital Eindhoven. Journal of Gastrointestinal Oncology. 2016;7:903.
  15. Larson DW (expert opinion). Mayo Clinic, Rochester, Minn. Nov. 30, 2016.